1. Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011;50(4):215–27.
2. Chung KF. Defining phenotypes in asthma: a step towards personalized medicine. Drugs. 2014;74(7):719–28.
3. Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy. 2014;7:53–65.
4. Food and Drug Administration. FDA approves Nucala to treat severe asthma. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471031.htm . Accessed 6 Nov 2015.
5. European Medicines Agency. Nucala (mepolizumab): summary of opinion. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003860/WC500194118.pdf . Accessed 13 Oct 2015.